| Nr. | Year OPEN | Title | users say | rate good | rate bad | no link | Citation |
|---|
Acetylsalicylic acid AspirinClopidogrelThalidomideGabapentinInflammation resolutionLipoxinStatinProtectinResolvinMaresinReceptor (Lipoxin)COX2FPR2 ALX| 1 | 2008 | Salicylate intolerance: pathophysiology, clinical spectrum, diagnosis and treatment. | 
| + | - | nl | Dtsch Arztebl Int 105(8):137-42 (2008) Baenkler HW |
| 2 | 2008 | Pharmacogenetics of aspirin resistance: a comprehensive systematic review. |
| + | - | nl | Br J Clin Pharmacol 66(2):222-32 (2008) Goodman T |
| 3 | 2007 | Aspirin resistance. |
| + | - | nl | Indian J Physiol Pharmacol 51(2):109-17 (2007) Ashwin KA |
| 4 | 2006 | Review article: gastrointestinal bleeding with low-dose aspirin - what's the risk? |
| + | - | nl | Aliment Pharmacol Ther 24(6):897-908 (2006) Laine L |
| 5 | 2009 | The present state of aspirin and clopidogrel resistance. |
| + | - | nl | Hamostaseologie 29(3):285-90 (2009) Guyer KE |
| 6 | 2008 | [Methods to evaluate aspirin and clopidogrel resistance]. |
| + | - | nl | Hamostaseologie 28(1-2):66-71 (2008) Weber AA |
| 7 | 2006 | [Resistance to acetylsalicylic acid and clopidogrel: current status]. |
| + | - | nl | Hamostaseologie 26(3):229-38 (2006) Mani H |
| 8 | 2003 | Aspirin resistance: definition, mechanisms and clinical read-outs. |
| + | - | nl | J Thromb Haemost 1(8):1710-3 (2003) Patrono C |
| 9 | 2005 | Narrative review: aspirin resistance and its clinical implications. |
| + | - | nl | Ann Intern Med 142(5):370-80 (2005) Sanderson S |
| 10 | 2002 | Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. |
| + | - | nl | Ann Intern Med 136(2):161-72 (2002) |
| 11 | 2002 | Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. |
| + | - | nl | Ann Intern Med 136(2):157-60 (2002) |
| 12 | 2000 | Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. |
| + | - | nl | Arch Neurol 57(3):326-32 (2000) Hart RG |
| 13 | 2000 | Aspirin. |
| + | - | nl | Circulation 101(10):1206-18 (2000) |
| 14 | 2008 | The role of aspirin in cardiovascular prevention: implications of aspirin resistance. |
| + | - | nl | J Am Coll Cardiol 51(19):1829-43 (2008) Gasparyan AY |
| 15 | 2010 | New uses for older drugs: the tales of aspirin, thalidomide, and gabapentin. |
| + | - | nl | Mayo Clin Proc 85(6):508-11 (2010) |
| 16 | 2010 | Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. |
| + | - | nl | Circulation 121(24):2694-701 (2010) |
| 17 | 2010 | Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. | 
| + | - | nl | Circ Res 107(10):1170-84 (2010) |
| 18 | 2008 | Aspirin: promise and resistance in the new millennium. |
| + | - | nl | Arterioscler Thromb Vasc Biol 28(3):s25-32 (2008) |
| 19 | 2010 | Lipoxin and aspirin-triggered lipoxins. |
| + | - | nl | ScientificWorldJournal 10(-):1048-64 (2010) |
| 20 | 2002 | Lipid-derived mediators in endogenous anti-inflammation and resolution: lipoxins and aspirin-triggered 15-epi-lipoxins. |
| + | - | nl | ScientificWorldJournal 2(-):169-204 (2002) |
| 21 | 2010 | Therapeutic applicability of anti-inflammatory and proresolving polyunsaturated fatty acid-derived lipid mediators. |
| + | - | nl | ScientificWorldJournal 10(-):676-712 (2010) |
| 22 | 2007 | Laboratory detection of 'aspirin resistance': what test should we use (if any)? |
| + | - | nl | Eur Heart J 28(14):1673-5 (2007) Cattaneo M |
| 23 | 2007 | Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. |
| + | - | nl | Blood 109(6):2285-92 (2007) |
| 24 | 2007 | Aspirin and clopidogrel resistance. |
| + | - | nl | Hematology Am Soc Hematol Educ Program -(-):114-20 (2007) |
| 25 | 2010 | Vane's discovery of the mechanism of action of aspirin changed our understanding of its clinical pharmacology. |
| + | - | nl | Pharmacol Rep 62(3):518-25 (2010) |
| 26 | 2005 | Aspirin resistance. |
| + | - | nl | Pharmacol Rep 57 Suppl(-):33-41 (2005) |
| 27 | 2007 | Resistance to aspirin and clopidogrel: possible mechanisms, laboratory investigation, and clinical significance. | 
| + | - | nl | Hellenic J Cardiol 48(6):352-63 (2007) |
